Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2011

Ultragenyx Raises $45M in Series A to Progress Lead Orphan Disease Candidate into Clinic

  • Orphan disease therapeutics startup Ultragenyx Pharmaceutical raised $45 million in a Series A financing round co-led by TPG Biotech and Fidelity Biosciences. Additional investors included HealthCap and Pappas Ventures.

    Ultragenyx will use the funds to expand and progress its rare disease products pipeline, including lead candidate UX-001, for the treatment of hereditary inclusion body myopathy, which is expected to start in clinical development during 2011. UX-001 is an extended-release formulation of sialic acid.

    The firm’s pipeline currently includes four other lysosomal disease/enzyme therapy candidates. It projects another two products may reach the clinic within the next one to two years. Founded in 2010 by Emil Kakkis, M.D., formerly BioMarin Pharmaceuticals’ CMP, Ultragenyx aims to select and develop candidates with clear mechanisms of action against untreated rare diseases.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »